Insight

Review of precision therapeutics and emerging strategies in HR+ MBC

Photo taken from Maxwell Lloyd/X

Aug 27, 2024, 17:21

Review of precision therapeutics and emerging strategies in HR+ MBC

Michelle DeMeo, Senior Program Manager at Dana-Farber Cancer Institute, shared on X:

“Congratulations to Maxwell Lloyd, Kevin Kalinsky, Aditya Bardia, Komal Jhaveri and Seth Wander for recently published review of precision therapeutics and emerging strategies in HR+ MBC (metastatic breast cancer) in Nature Reviews Clinical Oncology.”

Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer

Authors: Maxwell Lloyd, Kevin Kalinsky, Aditya Bardia, Komal Jhaveri and Seth Wander.

Source: Michelle DeMeo/X

Aditya Bardia cancer Dana-Farber Cancer Institute HR+ mBC Kevin Kalinsky Komal Jhaveri Maxwell Lloyd metastatic breast cancer Michelle DeMeo Nature Reviews Clinical Oncology OncoDaily Oncology precision therapeutics Seth Wander

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC